Aventis Pharma to deploy Pharsight's model-based drug development methodology and software
"Aventis Pharma is a true innovator among leading pharmaceutical companies," said Michael Perry, Pharsight President and CEO.
By on May 1, 2002"Aventis Pharma is a true innovator among leading pharmaceutical companies," said Michael Perry, Pharsight President and CEO. "Through this relationship, we will work together to support the Aventis Pharma strategy to streamline its clinical development processes."
Pharsight revealed its methodology is designed to integrate all relevant scientific, clinical, commercial and financial information about a drug into computer-based models, enabling a more value-driven program strategy. According to Pharsight the methodology uses computer-based modeling and simulation to better characterize the state of knowledge about a drug candidate, identify missing information and quantify its importance, and then design development programs designed to efficiently generate that information.
"We believe that Pharsight's methodology and software can facilitate more learning about the drug candidate much earlier in the development process," said Sol Rajfer, Senior Vice President, Product Realization, Aventis Pharma. "If we can do that, we can then make earlier `go or no go' decisions based on greater insight into the profile and market potential of the drug."
Details of the agreement and which drug candidates are included were not revealed.